{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:01:07Z","timestamp":1790823667857,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T00:00:00Z","timestamp":1550880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.kint.2019.01.041","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T21:38:08Z","timestamp":1551217088000},"page":"231-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de\u00a0novo kidney transplant patients"],"prefix":"10.1016","volume":"96","author":[{"given":"Claudia","family":"Sommerer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Suwelack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duska","family":"Dragun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Merville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Junge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Thaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Nashan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Almartine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Dantal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duska","family":"Dragun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Feldkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hazzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Heyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Meur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Merville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Morelon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Mousson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Muehlfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Nashan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemyslaw","family":"Pisarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Suwelack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Thaiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Thierry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wiesener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.01.041_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trre.2013.04.003","article-title":"The impact of calcineurin inhibitors on graft survival","volume":"27","author":"Rush","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.kint.2019.01.041_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/tri.12133","article-title":"Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome","volume":"26","author":"Vanhove","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2019.01.041_bib4","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","article-title":"Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation","volume":"14","author":"Knoll","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.01.041_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/OAJCT.S63058","article-title":"TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation","volume":"6","author":"Pascual","year":"2014","journal-title":"Open Access J Clin Trials"},{"key":"10.1016\/j.kint.2019.01.041_bib6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transplant Res"},{"key":"10.1016\/j.kint.2019.01.041_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.transproceed.2011.11.055","article-title":"Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience","volume":"44","author":"Santos","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2019.01.041_bib9","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1432-2277.2009.01010.x","article-title":"Effect of everolimus on skin cancers in calcineurin inhibitor-treated heart transplant recipients","volume":"23","author":"Euvrard","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2019.01.041_bib10","first-page":"4369574","article-title":"Everolimus and malignancy after solid organ transplantation: a clinical update","volume":"2016","author":"Holdaas","year":"2016","journal-title":"J\u00a0Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejca.2012.09.013","article-title":"Immunosuppression and Cancer Study Group. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009","volume":"49","author":"Piselli","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.kint.2019.01.041_bib12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","article-title":"Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients","volume":"93","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2019.01.041_bib13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.01.041_bib15","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-6143.2011.03504.x","article-title":"Chronic calcineurin inhibitor nephrotoxicity\u2014lest we forget","volume":"11","author":"Chapman","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib16","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.01.041_bib17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"for ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2019.01.041_bib18","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from month 3: a multicentre, randomized trial","volume":"32","author":"Budde","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib19","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.01.041_bib20","unstructured":"Certican\u00ae (Everolimus) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG."},{"key":"10.1016\/j.kint.2019.01.041_bib21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation-related but different","volume":"14","author":"Klawitter","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.kint.2019.01.041_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","article-title":"Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation","volume":"25","author":"Langer","year":"2012","journal-title":"Transplant Int"},{"key":"10.1016\/j.kint.2019.01.041_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ctr.12045","article-title":"Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine","volume":"27","author":"Shihab","year":"2013","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pst.511","article-title":"Designing a non-inferiority study in kidney transplantation: a case study","volume":"10","author":"Witte","year":"2011","journal-title":"Pharm Stat"},{"key":"10.1016\/j.kint.2019.01.041_bib25","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-6143.2009.02987.x","article-title":"Banff \u201909 meeting report: antibody mediated graft deterioration and implementation of Banff working groups","volume":"10","author":"Sis","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13063-016-1220-9","volume":"17","author":"Sommerer","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.kint.2019.01.041_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/FTD.0000000000000227","article-title":"Long-term follow-up of de novo use of mTOR and calcineurin inhibitors after kidney transplantation","volume":"38","author":"de Paula","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.kint.2019.01.041_bib28","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1111\/ajt.12852","article-title":"Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis","volume":"14","author":"Murakami","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2012.04334.x","article-title":"The effect of everolimus versus mycophenolate upon proteinuria following kidney transplantation and relationship to graft outcomes","volume":"13","author":"Wiseman","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib30","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/ndt\/gfw248","article-title":"Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?","volume":"31","author":"Halleck","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2019.01.041_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/TP.0b013e3181aa7d87","article-title":"RAD A2420 Study Group. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus","volume":"88","author":"Albano","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2019.01.041_bib32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/TP.0b013e3182551021","article-title":"Wound healing complications and the use of mammalian target of rapamycin inhibitors in kidney transplantation: a critical review of the literature","volume":"94","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2019.01.041_bib33","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.transproceed.2006.08.029","article-title":"Mycophenolate mofetil tolerability and dose changes in tacrolimus-treated renal allograft recipients","volume":"38","author":"Pascual","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2019.01.041_bib34","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/tid.12007","article-title":"Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation","volume":"15","author":"Kobashigawa","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2019.01.041_bib35","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/00007890-199506270-00007","article-title":"Predicting glomerular filtration rate after kidney transplantation","volume":"59","author":"Nankivell","year":"1995","journal-title":"Transplantation"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819301930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819301930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:53:16Z","timestamp":1758761596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819301930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0085253819301930"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.01.041","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de\u00a0novo kidney transplant patients","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}